| 2.79 -0.18 (-6.06%) | 07-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 3.72 | 1-year : | 4.34 |
| Resists | First : | 3.18 | Second : | 3.72 |
| Pivot price | 3.02 |
|||
| Supports | First : | 2.31 | Second : | 1.93 |
| MAs | MA(5) : | 3.2 |
MA(20) : | 2.95  |
| MA(100) : | 2.7 |
MA(250) : | 2.31 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 31.9 |
D(3) : | 57 |
| RSI | RSI(14): 45.6 |
|||
| 52-week | High : | 3.72 | Low : | 1.7 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ NKTX ] has closed above bottom band by 27.4%. Bollinger Bands are 17.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.03 - 3.05 | 3.05 - 3.06 |
| Low: | 2.69 - 2.72 | 2.72 - 2.73 |
| Close: | 2.76 - 2.79 | 2.79 - 2.82 |
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Fri, 26 Jun 2026
Nkarta sets June 30 fireside chat on CAR-NK autoimmune therapy - Stock Titan
Tue, 26 May 2026
NKTX - Nkarta Inc Stock Price and Quote - Finviz
Fri, 15 May 2026
Nkarta Insider Stock Sellers Must Be Relieved As Market Cap Falls To US$201m - simplywall.st
Thu, 14 May 2026
Here's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Situation - Yahoo Finance
Tue, 12 May 2026
Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights - GlobeNewswire
Fri, 17 Apr 2026
What date does Nkarta's (NKTX) report Earnings - Earnings Calendar & Announcement - Zacks Investment Research
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 72 (M) |
| Shares Float | 60 (M) |
| Held by Insiders | 4.8 (%) |
| Held by Institutions | 80.7 (%) |
| Shares Short | 3,380 (K) |
| Shares Short P.Month | 5,230 (K) |
| EPS | -1.36 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.01 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -17.2 % |
| Return on Equity (ttm) | -30.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.49 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -87 (M) |
| Levered Free Cash Flow | -57 (M) |
| PE Ratio | -2.07 |
| PEG Ratio | 0 |
| Price to Book value | 0.69 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.29 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|